BNP Paribas Financial Markets
PEAR

BNP Paribas Financial Markets’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

BNP Paribas Financial Markets’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-24,697
Closed -$50.4K – 4866
2022
Q3 		$50.4K Buy
+24,697
New +$41.9K ﹤0.01% 3977

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SGA
SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return

BNP Paribas Financial Markets's PEAR Position: Q4 2022 in Review

BNP Paribas Financial Markets sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q4 2022, closing a stake of 24,697 shares — an estimated $50.4K sold.

BNP Paribas Financial Markets first reported a position in PEAR in Q3 2022 and held it in 1 quarter. The position peaked at $50.4K in Q3 2022. 64 funds tracked by Wall St. Rank hold PEAR as of Q4 2022.

  • BNP Paribas Financial Markets reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 24,697 Pear Therapeutics, Inc. Class A Common Stock shares in Q4 2022, an estimated $50.4K.
  • BNP Paribas Financial Markets first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q3 2022 and held it in 1 quarter.
  • BNP Paribas Financial Markets's Pear Therapeutics, Inc. Class A Common Stock position peaked at $50.4K in Q3 2022.
  • 64 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q4 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2022, filed 14 Feb 2023.